Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06805461
Recruiting Observational

PumaRx Registry Trial

NCT06805461 · tracked via the Priya Life Science USA tracker
Sponsor
RenovoRx
Phase
Observational
Started
2025-08-01
Last updated
2026-03-30

Condition(s) studied

Solid Tumors

Investigational drug(s) / intervention(s)

RenovoCath®

RenovoCath®: Intra-arterial catheter delivery of chemotherapy agents for the collection of real-world data.

Study summary

This study is a multicenter, observational, post-marketing, registry study designed to track the safety and performance of the RenovoCath® device and assess survival outcomes in patients diagnosed with solid tumors who are treated with localized intra-arterial (IA) delivery of therapeutic agents to solid tumors using the RenovoCath® catheter.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Eligibility Criteria: 1. Male and female patients who have been diagnosed with solid tumor cancers and are at least 18 years of age at the time of the first IA procedure 2. Patients willing to provide informed consent and HIPAA release for use of their relevant medical records

Primary outcome measure(s)

  • Safety of RenovoCath® as assessed by the number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath. — From the time of the first treatment, until 30 days after the last treatment
    Number of participants experiencing adverse events related to the chemotherapy agents administered using RenovoCath.
  • Performance of RenovoCath® as assessed by the number of participants experiencing adverse events related to the inter-arterial drug delivery procedure. — From the time of the first treatment, until 30 days after the last treatment
    Track the performance of RenovoCath® in a real-world setting delivering a variety of therapeutic agents

Trial sites (3)

FacilityCityRegionStatus
Baptist Health South Florida Coral Gables Florida Recruiting
University of Pennsylvania Medical Center Pittsburgh Pennsylvania Recruiting
The University of Vermont Medical Center Burlington Vermont Recruiting

More RenovoRx trials in the USA

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Active, not recruiting

Other trials for the same condition

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies Recruiting
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors Recruiting
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Recruiting
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06805461 on ClinicalTrials.gov ↗ ← All trials in the USA